Abstract
BackgroundKN046 is a novel bispecific antibody targeting programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK),...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have